Preservative-free multidose dispenser approved across Europe for glaucoma treatment26 Feb 2019
Aptar Pharma working closely with Santen Pharmaceutical to improve patient safety, achieve dosing accuracy and maintain product integrity.
Aptar Pharma's innovative, preservative-free multidose Ophthalmic Squeeze Dispenser has been approved for Santen’s prescription drug Taflotan/Saflutan for the reduction of elevated intraocular pressure (IOP) in open-angle glaucoma and ocular hypertension in 26 countries in Europe.
This approval reconfirms the market-leading position of Aptar Pharma’s Ophthalmic Squeeze Dispenser as an approved delivery system for eye disease treatment formulations without any preservatives.
Meeting the needs of patients
Aptar Pharma is working closely with leading global ophthalmology specialist Santen Pharmaceutical to improve patient safety, achieve dosing accuracy and maintain product integrity. Santen is a specialized global pharmaceutical company dedicated to the ophthalmology field, and is spearheading the development and marketing of preservative-free drugs as part of its mission to contribute to the well-being of patients, their loved ones and society.
"We are delighted to launch preservative-free multidose formulations of these glaucoma therapies in Europe,” said Luis Iglesias, Corporate Officer and Head of EMEA, Santen. “By providing highly effective and well-tolerated, preservative-free medicines, with the option for multi-dose bottles, we hope to empower patients in their daily lives and improve the management of their condition.”
Chemical preservatives are often used in eye drops to ensure sterility of the drops in multidose bottles. When used in short-term treatments, they are mostly well-tolerated. For long-term use, such as in chronic conditions that include dry eye and glaucoma, preservative-free products are preferred. Preservatives have been known to cause signs and symptoms of irritation, allergy and ocular surface toxicity. Glaucoma patients use eye drops on a regular basis, and often for the rest of their lives.
BfArM, the German Regulatory Agency, approved Santen’s prescription drug Taflotan/Saflutan in the preservative-free multidose Ophthalmic Squeeze Dispenser in Germany as a first country in February 2017. Prior to this approval, Santen provided comprehensive and detailed microbiological study results as requested by BfArM. These showed that micro-organisms can neither survive nor form colonies in or on the container. The European registration process for several additional European countries ended positively and consequently, national marketing authorizations have been granted based on the European harmonized evaluation.
In addition, Santen performed usability studies that confirmed the user-friendliness of the multidose dispenser with glaucoma patients.
Making ophthalmic solutions easier and safer to deliver
Aptar Pharma’s Ophthalmic Squeeze Dispenser system is the result of more than 10 years of development and experience in the delivery of preservative-free ophthalmic solutions. Patients and consumers in the US, Europe, Latin America and Asia have benefited from this technology since 2012, with more than 175 commercial references now available on the market.
“Our Ophthalmic Dispenser technology has been a great success for our customers,” explained Matthias Birkhoff, VP Business Development, Aptar Pharma. “The proven and unrivalled microbiological safety, combined with a precise and reproducible drop ejection, allows pharmaceutical customers worldwide to enter into discussions with regulatory agencies such as the German BfArM with confidence.” Mr. Birkhoff also points out the user-friendliness of the system, adding “The ergonomic, pocket-size design and the intuitiveness of a squeezable container with a low actuation force certainly contribute to the high levels of acceptance among patients and consumers worldwide.”
Staying ahead of the market
Aptar Pharma's Ophthalmic Squeeze Dispenser provides a unique competitive advantage by addressing the worldwide trend towards patient-friendly, cost-effective and preservative-free multidose dispensers.
Eisai collaborates with University of Dundee on cancer drug discovery
10 Jul 2019
It is hoped that research into PROTACs will lead to new drug discoveries for proteins present in cancer, which are difficult to treat with conventional small molecule inhibitors.Read more
Onyx Scientific makes strategic investment in commercial API licence
10 Jul 2019
Investment fills the growing gap in the market for manufacturers that have the niche capabilities to deliver small-scale commercial API projects.Read more
I Holland to share the science behind tool maintenance
9 Jul 2019
Proper maintenance - rather than replacement - of compression tooling will improve profitability.Read more
Catalent extends global commercial spray drying capabilities in Europe
9 Jul 2019
Company's customers to have immediate access to Niro PSD2 and PSD4 spray driers, which are supported by dedicated clean area facilities for both solvent and aqueous processing of potent or non-potent drug formulations.Read more
Operations commence at Wasdell Group’s EU headquarters
8 Jul 2019
The new facility houses 11 bespoke production suites and temperature controlled high-way warehouses increases Wasdell’s capacity in clinical and commercial packaging, distribution & logistics and QP services.Read more
Porvair Sciences launches first Drosophila ChIP kits
4 Jul 2019
Offers a single optimised Chromatrap kit with unique buffers and components for Drosophila chromatin extraction and ChIP.Read more
Boehringer Ingelheim expands NASH R&D pipeline with new first-in-class compound
3 Jul 2019
Yuhan Corporation to receive up to USD 870 million in upfront and success-based development and commercialization milestones, excluding royalties.Read more
Fresh data on protein interactions in Alzheimer’s disease
2 Jul 2019
Demonstrates the unique ability of diffusional sizing to assess protein binding in-solution and for difficult-to-study systems.Read more
Fujifilm Irvine Scientific to open new cell culture media manufacturing site in Europe
2 Jul 2019
The space will support cGMP manufacturing of animal component-free, dry powder media, liquid media, and downstream bioprocessing liquids.Read more
Novartis bolsters ophthalmic portfolio with acquisition of Xiidra
1 Jul 2019
Xiidra 5% is the first and only prescription treatment approved to treat both signs and symptoms of dry eye by inhibiting inflammation caused by the disease.Read more
Are you a supplier
Here's what we can do for you
- Generate quality leads for your business
- Stay visible for 365 days of the year
- Receive product inquiries and respond to meeting requests directly
- Improve company online presence through Search Engine Optimisation